Glatiramer Acetate Articles
Copaxone driving Teva revenue growth
6 May 2002
Fast-track MS drug plan for the UK
25 February 2002
UK deal cuts MS drug prices by up to 26%
11 February 2002
UK govt/industry agree risk-share drug deal for MS
11 February 2002
Rebif panel meeting in USA cancelled
7 January 2002
Rebif panel meeting in USA cancelled
27 December 2001
Proneuron, Teva to collaborate on new glatiramer uses
6 December 2001
Net income up 23% at Schering AG as Betaferon sales stay strong
9 November 2001
Lundbeck earnings soar as citalopram sales continue to increase
7 November 2001
Teva posts equivocal data on oral Copaxone - UPDATE
20 September 2001
Teva posts equivocal data on oral Copaxone
17 September 2001
15 European countries approve Copaxone
8 August 2001
NICE PAD on MS drugs calls for talks on prices
7 August 2001
FDA approves extended label for Copaxone
23 July 2001
Unprecedented growth forecast for generics
18 June 2001
Pharma "now 71.5% of Israeli biotech sales"
25 May 2001
Cipramil sales driving Lundbeck growth
16 May 2001
Stock Commentary - New York
10 May 2001
Copaxone driving profit growth at Teva
4 May 2001
Further delays to NICE MS drug appraisal
31 January 2001
Teva launches MS drug Copaxone in UK
7 December 2000
Betaferon beats rivals to Japanese market
28 November 2000
Copaxone study shows six-year efficacy
23 August 2000
Teva's Copaxone approved in UK
16 August 2000
One-off R&D charges hit Teva's net income
2 August 2000
Teva progresses in CNS and autoimmune drugs
31 July 2000
Teva's Copaxone close to EU approval
5 June 2000
Teva net jumps 34%, US sales leap 43%
5 May 2000
Teva initiates global study with oral Copaxone in MS
27 April 2000
Copaxone pushes Teva FY profits up 39.3%
16 February 2000
Teva profits up 43% for third quarter
2 November 1999
AutoImmune shares collapse on Colloral data in rheumatoid arthritis
8 September 1999
HMR helps soften blow as Hoechst profits slide
5 August 1999
Teva profits soar 82% in 2nd quarter
4 August 1999
Teva earnings receive boost from Copaxone
13 May 1999
Copaxone approved in Switzerland
13 May 1999
Multiple sclerosis drug development update
4 March 1999
AutoImmune licenses MS patents to Teva
25 February 1999
Teva's fortunes take turn for the better
25 February 1999
Hungarian MS patients protest drug charges
15 January 1999
Biosintetica License Copaxone
18 August 1998
"Worst And Most Difficult Quarter" For Years at Teva
10 August 1998
Investors Falling Out Of Love With Teva?
19 May 1998
Teva Looking To Euro Buy As Profits Fall
13 May 1998
Good Prospects For Ares-Serono's Rebif?
26 March 1998
Strong Growth In Sales And Profits For Israel's Teva
3 March 1998
Teva Expects Higher 1997 Sales, Profits, But Lower 4th Qtr
16 February 1998
Betaferon Effective In Secondary Progressive MS
11 February 1998
Connetics MS Vaccine Clears Phase I/II Trial
21 January 1998
1997: Another Good Year For New Chemical Entities
6 January 1998
Teva Reports 74% Rise In Nine-Month Profits
19 November 1997
Canada Approves Copaxone
10 September 1997
Proteus Fights Back With Solid Pipeline
20 August 1997
Teva Posts Sharp Rises In 2nd Qtr Profits
11 August 1997
Copaxone Putting In Strong US Performance
7 August 1997
Teva's Strength: Coping With Change
21 July 1997
AutoImmune Shares Tumble As Myloral Fails In Ph III
24 April 1997
Copaxone Launched In The USA, Its Second Market
9 April 1997
Wall Street Disappointment With Biogen Hits Teva
26 March 1997
1996 A Year Of M&As For Teva Pharmaceuticals
3 March 1997
Record Number Of New Chemical Entities In 1996
20 January 1997
Copaxone Hopes Boost Teva's ADRs
13 January 1997
First Launch Of Teva's Copaxone For Multiple Sclerosis
6 January 1997
FDA Year-End Approval Spate As Expected
6 January 1997
Continued Approval Of Blockbuster Products In '97?
23 December 1996
Product News In 1996 Dominated By CNS
23 December 1996
Isreali Call For Biotech Venture Capital Fund
16 December 1996
First Approval Of Teva's MS Drug Copaxone
25 November 1996
Teva Receives Israeli Approval For Copaxone
18 November 1996
Teva Tempers Copaxone Profits Expectations
28 October 1996
Teva's Copaxone "Approvable" In USA
14 October 1996
NEW YORK STOCK COMMENT
30 September 1996
FDA Panel Advises Approval Of Teva's Copaxone
30 September 1996
"Significant Increases In Teva Sales And Profits"
2 September 1996
Teva Says Lemmon On Target As Share Price Falls
8 July 1996
Teva Pharmaceuticals Signs $70 Million Loan
17 June 1996
Teva's Copaxone Stalls In USA
20 May 1996
Buy Teva Shares Say US Analysts
29 April 1996
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- US Supreme Court says patent settlement can "sometimes" be illegal
